British pharmaceutical company Circassia has announced the termination of cooperation with AstraZeneca in the development and commercialization of two drugs for the treatment of COPD in the United States. This writes The Pharma Letter.
Under the terms of the agreement in 2017, the company conducted joint development of inhaled drugs acridine bromide and formoterol fumarate+ acridine bromide. Circassia also received the option to buy the rights to these drugs in the United States.
Now, however, AstraZeneca will have rights to medicines, as well as some additional assets. In turn, Circassia will be able to get rid of the debt owed to AstraZeneca.